ArticleInternational journal of clinical and experimental pathology2017
Effects of ASPP2 on proliferation and apoptosis of malignant spinal tumor cells.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- TP53BP2: Roles in suppressing tumorigenesis and therapeutic opportunities.Genes & diseases · 2023Review
- mRNA sequencing and CyTOF analysis revealed ASPP2 altered the response patterns of hepatocellular carcinoma HepG2 cells to usnic acid.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- ASPP2 promotes cell apoptosis in cervical cancer through inhibiting autophagy.Experimental and therapeutic medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant spinal tumors have rapid progression and destruct spines or other tissues, leading to metastasis of peripheral organs, causing high difficulty for surgery, recurrence and worse prognosis, thus severely affecting patient life quality and survival period. Apoptosis stimulating protein 2 of p53 (ASSP2) is one member of p53 binding protein family pro-apoptotic member, and can enhance apoptotic activity via modulating p53 pathway. Previous study found critical roles of ASPP2 in occurrence and progression of tumors, whilst the functional role of mechanism of ASPP2 on malignant spinal tumor cells has not been illustrated. Malignant spinal tumor tissue and adjacent tissues were collected for testing ASPP2 mRNA and protein expression in real-time PCR and Western blot. ASPP2 over-expression vector was used to transfect tumor cells, whilst MTT assay was employed for tumor proliferation, followed by p53 expression in Western blot. Caspase 3 activity assay was employed for testing the effect on cell apoptosis. Flow cytometry was employed for tumor cell apoptosis. Real-time PCR tested expressional change of Bcl2 and Bax. ASPP2 mRNA/protein level was significantly depressed in malignant spinal tumor tissues (P<0.05 compared to adjacent tissues). ASPP2-overexpression vector transfection tumor cells increased apoptosis and inhibited proliferation, accompanied with lower Bcl-2, higher Bax, Caspase 3 and p53 (P<0.05 compared to control group). ASPP2 is down-regulated in malignant spinal tumor tissues. ASPP2 can inhibit malignant spinal tumor cell proliferation via mediating p53 expression for cell apoptosis, thus can work as one molecular target for tumor diagnosis and prognostic analysis.
Indexed as
Identifiers
31966654PMC6965233W3006750423What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.